Study guide

13.3 Recommending Treatment Modifications

APC Intern Written Examination Exam

Track your progress as you read

Finished sections get a check mark.

1 Introduction & Exam Overview

1.1 Current Exam Facts 1.2 Pathway to General Registration 1.3 Restricted Open-Book Strategy (AMH & APF) 1.4 Scoring, Results & Appeals

2 Legal Framework: PBS & Medicine Schedules

2.1 PBS, Authority Prescriptions & Special Access Scheme 2.2 Schedules 2 & 3 (Pharmacy & Pharmacist Only Medicines) 2.3 Schedules 4 & 8 (Prescription Only & Controlled Drugs)

3 Legal Framework: Privacy, National Law & Pharmacy Board

3.1 Privacy, Confidentiality & Patient Rights 3.2 Health Practitioner National Law & Registration 3.3 Pharmacy Board Codes, Guidelines & Standards

4 Patient-Centred Medication Management

4.1 Assessing Clinical Situations & Treatment Options 4.2 Patient Factors: Adherence, Efficacy & Safety 4.3 Drug & Dosage-Form Factors 4.4 Culturally Responsive Medication Management

5 Primary Care & Judicious Use of Medicines

5.1 Primary Care & OTC Assessment 5.2 Judicious Use of Antimicrobials & High-Risk Agents 5.3 Non-Pharmacological Options & Evidence-Based OTC Choices

6 Dispensing & Clinical Appropriateness

6.1 Prescription Evaluation 6.2 Clinical Appropriateness Checks 6.3 Labelling, Packaging & Dispensing Standards 6.4 Communicating with Prescribers & Documenting Changes

7 Counselling & Acute Care

7.1 Patient-Centred Counselling 7.2 Confirming Understanding & Lifestyle Counselling 7.3 Acute Illness, Injury & Emergency Response

8 Therapeutics: Cardiovascular & Endocrine

8.1 Hypertension & Heart Failure 8.2 Ischaemic Heart Disease & Anticoagulation 8.3 Diabetes Medicines 8.4 Thyroid & Lipid Disorders

9 Therapeutics: Infection, Respiratory & Gastrointestinal

9.1 Anti-Infectives & Infection Management 9.2 Asthma & COPD 9.3 Gastrointestinal & Hepatic Conditions 9.4 Vaccination & Travel Health

10 Therapeutics: Neurology, Psychiatry & Pain

10.1 Epilepsy & Movement Disorders 10.2 Depression, Anxiety & Psychosis 10.3 Pain Management & Opioids 10.4 Migraine & Common Analgesics

11 Therapeutics: Special Populations & Systems

11.1 Women's Health, Contraception & Pregnancy 11.2 Dermatology, Ophthalmology & ENT 11.3 Renal/Hepatic Impairment & Dose Adjustment

12 Therapeutics: Rheumatology, Haematology, Urology, Oncology & Toxicology

12.1 Rheumatology: Gout, Osteoarthritis & Inflammatory Arthritis 12.2 Haematology: Anaemias & Blood Safety Monitoring 12.3 Urology & Men's Health 12.4 Oncology Support & Oral Anticancer Medicines 12.5 Toxicology & Poisoning Management

13 Monitoring: Clinical Review

13.1 Clinical Review Process 13.2 Interpreting Laboratory & Clinical Monitoring 13.3 Recommending Treatment Modifications

14 Monitoring: Safety & Adverse Drug Reactions

14.1 Adverse Drug Reactions & Reporting 14.2 Allergies, Sensitivities & Cross-Reactivity 14.3 High-Risk Medicines Monitoring

15 Compounding Medicines

15.1 Determining Required Formulations 15.2 Compounding Standards & Quality 15.3 Patient-Specific Preparations

16 Pharmaceutical Calculations

16.1 Dosage Calculations 16.2 Concentrations, Dilutions & Alligation 16.3 Half-Life & Basic Kinetic Calculations

17 Promote Health & Well-Being

17.1 National & Local Health Priorities 17.2 Screening Programs & Pharmacist Role 17.3 Culturally Responsive Promotion & Self-Sufficiency

13.3 Recommending Treatment Modifications

Key Takeaways Explain This Topic AI

Treatment modification options include dose change, switch, deprescribe, add monitoring, refer, or strengthen non-drug care—chosen against evidence and patient values.

Communicate recommendations with clear rationale, urgency, and a monitoring plan; document what was advised and agreed.

Titrate stepwise where onset is delayed (antihypertensives, antidepressants) and avoid premature “failure” labels before adequate trial duration.

Stop high-risk medicines safely: benzodiazepine and related sedative tapers; avoid abrupt beta-blocker withdrawal when clinically inappropriate.

Deprescribing is an active intervention with goals, taper strategy, and follow-up—not simply deleting a line from the dispensing history.

Last updated: August 2026

12.3 Recommending Treatment Modifications

Quick Answer: When monitoring shows therapy is off target or unsafe, recommend a specific modification : change dose , switch , deprescribe , add monitoring , refer , or optimise non-drug care . Base advice on evidence + patient values + clinical status , communicate collaboratively, plan titration or taper , and document rationale . Abrupt stops of benzodiazepines or beta-blockers can be dangerous—use structured withdrawal thinking.

Section 13.1 finds problems; Section 13.2 interprets data; this section turns findings into actionable recommendations —the decision-making heart of Standard 3.3 .

When modification is indicated

Consider change when one or more of the following is true:

  • Goal not met after an adequate trial (dose, duration, adherence verified)
  • Harm exceeds benefit (ADR, high-risk interaction, fall risk, cognitive impairment)
  • Indication resolved or was never valid (candidate for deprescribing)
  • Organ function changed (renal/hepatic decline requires dose or drug change)
  • Life stage changed (pregnancy potential, frailty, palliative goals)
  • Adherence barriers make the current regimen unworkable (complexity, cost, formulation)

Do not modify solely because a computer alert fired without clinical relevance, or because a single mild lab drift is expected and already managed.

The modification menu

Action When it fits Exam cautions

Increase dose / intensify Partial response, tolerating current dose, room within range Confirm adherence first; respect max doses and monitoring

Decrease dose ADR likely dose-related; organ impairment; overshoot of target May need slower steps for some drugs

Switch within/between classes Class ADR (ACEI cough → ARB concept); failure despite adherence Watch washout/interactions (for example MAOI concepts)

Add agent Compelling indication for combination (BP, HFrEF, diabetes cardiorenal) Avoid irrational duplicates (two NSAIDs)

Deprescribe / stop No indication, cumulative harm, time-limited therapy finished Plan taper if dependence/rebound risk

Add monitoring only Early therapy, interaction period, uncertain but not yet unsafe Set a review date—monitoring is not indefinite deferral of needed change

Non-drug care Lifestyle, physio, CBT access, device technique, salt/fluid advice Often first-line or synergistic; not a dismissal of real disease

Refer / escalate Red flags, scope limits, complex mental health, acute decompensation Pharmacists escalate when safety requires it

Evidence and patient values

Best-practice recommendations weigh:

Evidence — guideline-directed options, AMH/APF-aligned dosing and cautions, known outcome data (for example prognostic pillars in HFrEF).

Clinical status — comorbidities, labs, allergies, interacting drugs.

Patient values — priorities (avoiding sexual side effects, preserving independence, cost, cultural preferences, fertility).

Practicality — regimen complexity, carer support, dose administration aids, PBS access realities.

A “guideline-perfect” regimen the patient will not take is a failed plan. Shared decisions may accept a slightly less intensive regimen that is actually used safely .

Communicating recommendations

Use a concise clinical structure when contacting prescribers or explaining to patients:

  • Situation: who the patient is and the relevant therapy
  • Background: indication, recent changes, adherence, key results
  • Assessment: the prioritised drug-related problem
  • Recommendation: specific, feasible next step with monitoring

Example tone: “Blood pressure remains above target on low-dose ACE inhibitor with good adherence; potassium and creatinine are stable. Suggest stepwise dose increase with repeat electrolytes/renal function, unless you prefer adding a CCB because of cough risk historically.”

Avoid vague statements (“maybe review meds sometime”) and avoid overstepping scope (“I have already stopped your specialist’s chemotherapy”). For prescription changes, recommend and facilitate —do not invent unlawful supply.

  • Stepwise titration examples
  • Antihypertensives

Confirm technique, adherence, and white-coat issues before stacking drugs.

Intensify in steps : optimise dose of first agent or add a second first-line class per individualised plan.

Recheck BP response and electrolytes/renal function when ACEI/ARB/diuretic doses change.

In older/frail patients, slower titration and fall-risk awareness matter as much as the millimetres of mercury.

Antidepressants — onset and adequate trial

Many antidepressants need weeks for meaningful response; early adverse effects (nausea, activation, sexual dysfunction) may appear sooner.

Do not label “treatment failure” after a few days of low-dose therapy without considering onset time, adherence, and dose optimisation.

Discuss suicide risk monitoring early in therapy or after dose changes, especially in younger people—safety planning and urgent referral rules apply.

Switching strategies (and any washout needs for particular classes) should follow evidence and specialist advice when complex.

Analgesics and other symptom-driven therapy

Titrate to function and safety , not only pain scores.

Step down when acute pain drivers resolve; prolonged high-dose opioids without review is a modification opportunity (deprescribe/taper plan with the prescriber).

  • Stopping high-risk medicines safely
  • Benzodiazepines and Z-drugs (concepts)

Long-term benzodiazepine use risks dependence, falls, and cognitive effects. Abrupt cessation after prolonged use can precipitate withdrawal (anxiety rebound, insomnia, tremor, in severe cases seizures). Safe approaches emphasise:

  • Shared decision and gradual dose taper over an individualised period
  • Possibly converting to a longer-acting agent in some specialist-guided strategies
  • Non-drug sleep/anxiety supports
  • Monitoring for withdrawal and relapse of original symptoms
  • Avoiding simply “running out and stopping” without a plan

Intern exam items often test recognition that sudden stop is unsafe after chronic use, not the exact milligram schedule of every taper protocol.

Beta-blockers

Abrupt withdrawal of beta-blockers can be associated with rebound tachycardia, hypertension, or worsening angina in at-risk patients. When beta-blockers are to be stopped, gradual dose reduction under medical direction is the usual safety message—especially in ischaemic heart disease. Do not advise cold-turkey cessation for convenience when a prescription ends without review.

Other taper/rebound examples (awareness)

Long-term systemic corticosteroids: adrenal insufficiency risk if stopped abruptly after significant exposure—specialist/medical taper plans.

Some antidepressants: discontinuation symptoms if stopped suddenly—slow reduction often preferred.

Anticonvulsants and other CNS medicines: seizure risk if stopped abruptly—never recommend unsupervised sudden cessation.

Deprescribing as a positive intervention

Deprescribing is planned withdrawal of medicines that are no longer beneficial or are harmful. Steps:

  • Agree the target medicine and goal (stop vs reduce)
  • Check dependence/rebound potential → taper vs stop
  • Sequence one major change at a time when possible
  • Provide symptomatic supports and non-drug alternatives
  • Book follow-up for efficacy, withdrawal, and recurrence
  • Update allergy/ADR records if a true reaction prompted the stop

Polypharmacy in older people is a frequent setting: anticholinergics, sedatives, long-term PPIs without indication, and duplicate therapies are common candidates—always individualise.

Document the rationale

Documentation should capture:

  • Problem identified (linked to goal or harm)
  • Evidence/clinical triggers (labs, symptoms, adherence findings)
  • Options considered
  • Recommendation made and to whom
  • Patient understanding and preferences
  • Monitoring and follow-up timing
  • Outcome when known (closed loop)

Good records protect patients at handover and demonstrate Standard 3.3 competence. On the exam, the “best answer” usually pairs a safe specific action with communication and monitoring , not silent unilateral extremes.

Putting modifications into one clinical story

A patient on chronic diazepam, ramipril, and incomplete antidepressant response presents with falls and persistent low mood. Prioritise: assess sedation/fall contribution → collaborative benzodiazepine taper plan (not abrupt stop) → verify antidepressant dose/duration/adherence before declaring failure → check BP, renal function, potassium if intensifying ramipril later → document and follow up. That sequence is clinical review converted into safer therapy.

Treatment modification is where monitoring becomes care: choose the right change, make it safely, say it clearly, write it down, and check it worked.